-
Product Insights
Net Present Value Model: Kanuma
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Kanuma Drug Details Sebelipase alfa (SBC-102,...
-
Product Insights
Net Present Value Model: TLX-101
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model TLX-101 Drug Details ACD-101 (131I-ACD-101) is...
-
Product Insights
Net Present Value Model: Myozyme/Lumizyme
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Myozyme/Lumizyme Drug Details Alglucosidase alfa (Myozyme)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – pegtibatinase
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry pegtibatinase Drug Details Pegtibatinase (OT-58) is under development for the treatment of homocystinuria. It...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TAK-611
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TAK-611 Drug Details TAK-611 (SHP-611, HGT-1110, recombinant human arylsulfatase A) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – velmanase alfa
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry velmanase alfa Drug Details Velmanase alfa (Lamzede) is a recombinant human alpha mannosidase developed...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AGT-181
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AGT-181 Drug Details AGT-181 (HIRMAb-IDUA) is an investigational enzyme replacement therapy (ERT) for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ACD-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ACD-101 Drug Details ACD-101 (131I-ACD-101) is under development for the treatment of glioblastoma multiforme,...
-
Report Bundle
58% offTech in Pharma – Report Bundle (7 Reports)
Tech in Pharma Bundle Report Overview Although the pharmaceutical industry had been slow to adopt technological innovations, the onset of COVID-19 has dramatically altered the situation. The latest technologies, Augmented Reality (AR), Big Data, and Artificial Intelligence (AI), among others, will assist pharmaceutical companies in speeding up the research and development process, creating personalized products, and conducting testing in novel ways. Finally, these technologies will improve healthcare effectiveness and efficiency thereby transforming the patient and provider experience. Explore actionable market...
-
Thematic Analysis
Virtual Clinical Trials – Thematic Research
Virtual clinical trials, also commonly referred to as decentralized clinical trials (DCTs), use digital technologies and other processes that differ from traditional trial models to bring research closer to patient’s homes in order to increase access to trials, as well as reduce inconvenience and burden on participants by decreasing the number of physical site visits. Virtual trials are also known as remote, siteless, hybrid, or digital trials. The examples of digital technologies used in virtual trials includes eConsent, telemedicine, electronic...